FOLD
Amicus Therapeutics, Inc.NASDAQHealthcare$14.44+0.00%ClosedMarket Cap: $4.53B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
16.28
P/S
7.15
EV/EBITDA
89.33
DCF Value
$-29.48
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
5.2%
Net Margin
-4.3%
ROE
-12.0%
ROA
-2.9%
ROIC
-645.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $185.2M | 84.6% | $15.9M | $1.7M | $0.01 | — |
| FY 2025 | $634.2M | 87.3% | $34.5M | $-27.1M | $-0.09 | — |
| Q3 2025 | $169.1M | 87.4% | $34.3M | $17.3M | $0.06 | — |
| Q2 2025 | $154.7M | 90.2% | $-9.5M | $-24.4M | $-0.08 | — |
| Q1 2025 | $125.2M | 90.7% | $-8.0M | $-21.7M | $-0.07 | — |
| Q4 2024 | $149.7M | 90.1% | $16.0M | $14.7M | $0.05 | — |
| FY 2024 | $528.3M | 90.0% | $24.9M | $-56.1M | $-0.18 | — |
| Q3 2024 | $141.5M | 90.6% | $21.7M | $-6.7M | $-0.02 | — |
| Q2 2024 | $126.7M | 91.1% | $15.0M | $-15.7M | $-0.05 | — |
| Q1 2024 | $110.4M | 87.7% | $-27.7M | $-48.4M | $-0.16 | — |
| Q4 2023 | $115.1M | 90.2% | $-3.7M | $-33.8M | $-0.12 | — |
| FY 2023 | $399.4M | 90.7% | $-77.2M | $-151.6M | $-0.51 | — |